Area of research
Molecular Biology · Cancer Research
Research interest
The main area of our research involves the use of high resolution mass spectrometry to quantitatively study protein complexes, post-translational modifications, metabolomics and lipidomics in signaling pathways for diseases such as cancer. The goal is to identify new targets for drugs that specifically inhibit the defective pathways that are driving cell growth, proliferation and metastasis. We recently developed a mass spectrometry approach for label-free quantitative proteomics based on the average and total signal values of the peptide LC/MS/MS spectra identified from each protein.
Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle
Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8+ T cells to suppress anti-tumor immunity
Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome
PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity
A phosphate-sensing organelle regulates phosphate and tissue homeostasis
AMPK-dependent phosphorylation of the GATOR2 component WDR24 suppresses glucose-mediated mTORC1 activation
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
NADK-mediated de novo NADP(H) synthesis is a metabolic adaptation essential for breast cancer metastasis
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Altered propionate metabolism contributes to tumour progression and aggressiveness
PI3K drives the de novo synthesis of coenzyme A from vitamin B5
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Lysosomal cystine mobilization shapes the response of TORC1 and tissue growth to fasting
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
mTORC1 regulates a lysosome-dependent adaptive shift in intracellular lipid species
Suppression of nuclear GSK3 signaling promotes serine/one-carbon metabolism and confers metabolic vulnerability in lung cancer cells
Prolonged deprivation of arginine or leucine induces PI3K/Akt-dependent reactivation of mTORC1
Trans-omics analysis of insulin action reveals a cell growth subnetwork which co-regulates anabolic processes
Fatty acid synthesis is required for breast cancer brain metastasis
GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis
The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals
Proteomics of protein trafficking by in vivo tissue-specific labeling
mTORC1-chaperonin CCT signaling regulates m <sup>6</sup> A RNA methylation to suppress autophagy
Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer
Age-induced accumulation of methylmalonic acid promotes tumour progression
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle